Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

References for PMC Articles for PubMed (Select 20484628)

1.

Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist.

Cronican AA, Fitz NF, Pham T, Fogg A, Kifer B, Koldamova R, Lefterov I.

Biochem Pharmacol. 2010 May 1;79(9):1310-6. doi: 10.1016/j.bcp.2009.12.018. Epub 2010 Jan 8.

2.

Differential effects of dietary fatty acids on the cerebral distribution of plasma-derived apo B lipoproteins with amyloid-beta.

Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington CL, Johnsen RD, Dhaliwal SS, Mamo JC.

Br J Nutr. 2010 Mar;103(5):652-62. doi: 10.1017/S0007114509992194. Epub 2009 Oct 28.

PMID:
19860996
3.

The role of apolipoprotein E in Alzheimer's disease.

Kim J, Basak JM, Holtzman DM.

Neuron. 2009 Aug 13;63(3):287-303. doi: 10.1016/j.neuron.2009.06.026. Review.

4.

Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice.

Peng D, Hiipakka RA, Xie JT, Reardon CA, Getz GS, Liao S.

Atherosclerosis. 2010 Jan;208(1):126-33. doi: 10.1016/j.atherosclerosis.2009.07.016. Epub 2009 Jul 8.

5.

Memory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomers.

Lefterov I, Fitz NF, Cronican A, Lefterov P, Staufenbiel M, Koldamova R.

ASN Neuro. 2009 Apr 30;1(2). pii: e00006. doi: 10.1042/AN20090015.

6.

Regulation of macrophage function in inflammation and atherosclerosis.

Shibata N, Glass CK.

J Lipid Res. 2009 Apr;50 Suppl:S277-81. doi: 10.1194/jlr.R800063-JLR200. Epub 2008 Nov 5. Review.

7.

ApoE promotes the proteolytic degradation of Abeta.

Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE.

Neuron. 2008 Jun 12;58(5):681-93. doi: 10.1016/j.neuron.2008.04.010.

8.

High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice.

Thirumangalakudi L, Prakasam A, Zhang R, Bimonte-Nelson H, Sambamurti K, Kindy MS, Bhat NR.

J Neurochem. 2008 Jul;106(1):475-85. doi: 10.1111/j.1471-4159.2008.05415.x. Epub 2008 Jul 1.

9.

Dietary influences on cognitive function with aging: from high-fat diets to healthful eating.

Parrott MD, Greenwood CE.

Ann N Y Acad Sci. 2007 Oct;1114:389-97. Review.

PMID:
17986600
10.

Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment.

Lefterov I, Bookout A, Wang Z, Staufenbiel M, Mangelsdorf D, Koldamova R.

Mol Neurodegener. 2007 Oct 22;2:20.

11.

Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors.

Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10601-6. Epub 2007 Jun 11.

12.

Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach.

Koldamova R, Lefterov I.

Curr Alzheimer Res. 2007 Apr;4(2):171-8. Review.

PMID:
17430243
13.

The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease.

Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS.

Mol Cell Neurosci. 2007 Apr;34(4):621-8. Epub 2007 Jan 25.

PMID:
17336088
14.

Mediterranean diet, Alzheimer disease, and vascular mediation.

Scarmeas N, Stern Y, Mayeux R, Luchsinger JA.

Arch Neurol. 2006 Dec;63(12):1709-17. Epub 2006 Oct 9.

15.

LXRS and FXR: the yin and yang of cholesterol and fat metabolism.

Kalaany NY, Mangelsdorf DJ.

Annu Rev Physiol. 2006;68:159-91. Review.

PMID:
16460270
16.

Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease.

Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A.

Arch Neurol. 2005 Oct;62(10):1556-60.

PMID:
16216938
17.

Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice.

Koldamova R, Staufenbiel M, Lefterov I.

J Biol Chem. 2005 Dec 30;280(52):43224-35. Epub 2005 Oct 5.

18.

Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease.

Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM.

J Biol Chem. 2005 Dec 30;280(52):43236-42. Epub 2005 Oct 5.

19.

The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease.

Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, Poirier J, Van Nostrand W, Wellington CL.

J Biol Chem. 2005 Dec 30;280(52):43243-56. Epub 2005 Oct 5.

20.

Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study.

Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC; Cache County Study investigators.

Arch Gen Psychiatry. 2005 Feb;62(2):217-24.

PMID:
15699299
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk